<table id="ID637" width="100%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<caption>Table 18Summary of Effect of Coadministered Drugs on Exposure to Active Moiety(Risperidone + 9-Hydroxy-Risperidone) in Healthy Subjects or Patients withSchizophrenia</caption>
<col span="1" width="18%"></col>
<col span="1" width="18%"></col>
<col span="1" width="14%"></col>
<col span="1" width="16%"></col>
<col span="1" width="9%"></col>
<col span="1" width="25%"></col>
<tbody>
<tr>
<td>Coadministered Drug<br/>
</td>
<td>Dosing Schedule<br/>
</td>
<td>
<br/>
</td>
<td>Effect on Active<br/>Moiety<br/>(Risperidone + 9-<br/>Hydroxy-<br/>Risperidone (Ratio*)<br/>
</td>
<td>
<br/>
</td>
<td>Risperidone Dose<br/>Recommendation<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>Coadministered Drug<br/>
</td>
<td>Risperidone<br/>
</td>
<td>AUC<br/>
</td>
<td>C<sub>m</sub>
<sub>a</sub>
<sub>x</sub>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Enzyme (CYP2D6) <br/>Inhibitors <br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Fluoxetine <br/>
</td>
<td>20 mg/day<br/>
</td>
<td>2 or 3 mg twice<br/>daily<br/>
</td>
<td>1.4<br/>
</td>
<td>1.5<br/>
</td>
<td>Re-evaluate dosing. Do not exceed 8 mg/day<br/>
</td>
</tr>
<tr>
<td>Paroxetine <br/>
</td>
<td>10 mg/day<br/>
</td>
<td>4 mg/day<br/>
</td>
<td>1.3<br/>
</td>
<td>-<br/>
</td>
<td>Re-evaluate dosing. <br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>20 mg/day<br/>
</td>
<td>4 mg/day<br/>
</td>
<td>1.6<br/>
</td>
<td>-<br/>
</td>
<td>Do not exceed 8 mg/day<br/>
</td>
</tr>
<tr>
<td>
<br/>
</td>
<td>40 mg/day<br/>
</td>
<td>4 mg/day<br/>
</td>
<td>1.8<br/>
</td>
<td>-<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Enzyme (CYP3A/ <br/>PgP inducers) <br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Carbamazepine <br/>
</td>
<td>573 ± 168 mg/day<br/>
</td>
<td>3 mg twice daily<br/>
</td>
<td>0.51<br/>
</td>
<td>0.55<br/>
</td>
<td>Titrate dose upwards.<br/>Do not exceed twice the patient’s usual dose<br/>
</td>
</tr>
<tr>
<td>Enzyme (CYP3A) <br/>Inhibitors <br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Ranitidine <br/>
</td>
<td>150 mg twice daily<br/>
</td>
<td>1 mg single dose<br/>
</td>
<td>1.2<br/>
</td>
<td>1.4<br/>
</td>
<td>Dose adjustment not<br/>needed<br/>
</td>
</tr>
<tr>
<td>Cimetidine <br/>
</td>
<td>400 mg twice daily<br/>
</td>
<td>1 mg single dose<br/>
</td>
<td>1.1<br/>
</td>
<td>1.3<br/>
</td>
<td>Dose adjustment not<br/>needed<br/>
</td>
</tr>
<tr>
<td>Erythromycin <br/>
</td>
<td>500 mg four times<br/>daily<br/>
</td>
<td>1 mg single dose<br/>
</td>
<td>1.1<br/>
</td>
<td>0.94<br/>
</td>
<td>Dose adjustment not<br/>needed<br/>
</td>
</tr>
<tr>
<td>Other Drugs <br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
<td>
<br/>
</td>
</tr>
<tr>
<td>Amitriptyline <br/>
</td>
<td>50 mg twice daily<br/>
</td>
<td>3 mg twice daily<br/>
</td>
<td>1.2<br/>
</td>
<td>1.1<br/>
</td>
<td>Dose adjustment not<br/>needed<br/>
</td>
</tr>
<tr>
<td>
<paragraph>*Change relative to reference<br/>
</paragraph>
</td>
</tr>
</tbody>
</table>